Where Will Zai Lab Ltd - ADR (ZLAB) Stock Go Next After It Is Up 15.60% in a Week?

The market has been high on Zai Lab Ltd - ADR (ZLAB) stock recently. ZLAB gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Zai Lab Ltd - ADR has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ZLAB!

See Full ZLAB Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ZLAB Stock Today?

Zai Lab Ltd - ADR (ZLAB) stock is trading at $38.60 as of 3:24 PM on Wednesday, Nov 30, a rise of $4.91, or 14.57% from the previous closing price of $33.69. The stock has traded between $34.31 and $39.30 so far today. Volume today is less active than usual. So far 468,200 shares have traded compared to average volume of 728,166 shares. To see InvestorsObserver's Sentiment Score for Zai Lab Ltd - ADR click here.

More About Zai Lab Ltd - ADR

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC. The other product candidate includes Fugan, ZL-2302, and ZL-1101. Click Here to get the full Stock Report for Zai Lab Ltd - ADR stock.